Free Trial
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q1 2024 Earnings Report

Innoviva logo
$22.80 +0.28 (+1.24%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$22.82 +0.02 (+0.07%)
As of 05/7/2026 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innoviva EPS Results

Actual EPS
$0.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$77.50 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q1 2024
Date
5/8/2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Innoviva's Q1 2024 Press ReleasePress Release
(8-K)
Innoviva's Q1 2024 Quarterly reportQuarterly report
(10-Q)

Innoviva Earnings Headlines

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
May 6 at 4:05 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260506873256/en/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress/
Innoviva, Inc. (INVA) Stock Price, News, Quote & History - Yahoo Finance
April 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/INVA/
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
 |  Paradigm Press (Ad)
Analysts see this pharma stock surging 60%; eyes fresh entry
April 2, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/analysts-see-this-pharma-stock-surging-60-eyes-fresh-entry/ar-AA201bwC
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
March 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/theravance-secures-long-term-yupelri-patent-litigation-settlement?utm_source=marketbeat.com&utm_medium=referral
Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains
March 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/time-revisit-innoviva-inva-strong-080630212.html
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

View Innoviva Profile
Earnings Tools